141 results on '"Tabbò, F."'
Search Results
2. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
- Author
-
Gobbini, E., Chiari, R., Pizzutillo, P., Bordi, P., Ghilardi, L., Pilotto, S., Osman, G., Cappuzzo, F., Cecere, F., Riccardi, F., Scotti, V., Martelli, O., Borra, G., Maiello, E., Rossi, A., Graziano, P., Gregorc, V., Casartelli, C., Sergi, C., Del Conte, A., Delmonte, A., Bareggi, C., Cortinovis, D., Rizzo, P., Tabbò, F., Rossi, G., Bria, E., Galetta, D., Tiseo, M., Di Maio, M., and Novello, S.
- Published
- 2020
- Full Text
- View/download PDF
3. Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions
- Author
-
Marinello, A., primary, Vasseur, D., additional, Conci, N., additional, Lindsay, C., additional, Metro, G., additional, Ferrara, R., additional, Eisert, A., additional, Citarella, F., additional, Fallet, V., additional, Audugier-Valette, C., additional, Cousin, S., additional, Tabbò, F., additional, Russo, A., additional, Calles Blanco, A., additional, Iranzo Gomez, P., additional, Tagliamento, M., additional, Mezquita, L., additional, Ponce, S., additional, Besse, B., additional, and Aldea, M., additional
- Published
- 2022
- Full Text
- View/download PDF
4. EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity
- Author
-
Passiglia, F., primary, Righi, L., additional, Listì, A., additional, Tabbò, F., additional, Bironzo, P., additional, Reale, M.L., additional, Sini, C., additional, Vallone, S., additional, Arizio, F., additional, Parravicini, M.V. Pacchiana, additional, Mazilu, L., additional, Linardou, H., additional, Roca, E., additional, Buffoni, L., additional, Mohorcic, K., additional, Barbieri, V., additional, Pignataro, D., additional, Araujo, A., additional, Ares, L. Paz, additional, Felip, E., additional, Secen, N., additional, Comanescu, A., additional, Szmytke, E., additional, Scagliotti, G., additional, and Novello, S., additional
- Published
- 2022
- Full Text
- View/download PDF
5. 1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC
- Author
-
Marinello, A., primary, Vasseur, D., additional, Conci, N., additional, Fallet, V., additional, Audigier-Valette, C., additional, Cousin, S., additional, Tabbò, F., additional, Guisier, F., additional, Russo, A., additional, Calles Blanco, A., additional, Metro, G., additional, Massa, G., additional, Citarella, F., additional, Eisert, A.K., additional, Iranzo Gomez, P., additional, Tagliamento, M., additional, Mezquita, L., additional, Lindsay, C., additional, Ponce, S., additional, and Aldea, M., additional
- Published
- 2022
- Full Text
- View/download PDF
6. 34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions
- Author
-
Marinello, A., primary, Duruisseaux, M., additional, Zrafi, W.S., additional, Dall'Olio, F.G., additional, Massa, G., additional, Iranzo, P., additional, Tabbò, F., additional, Guisier, F., additional, Lindsay, C., additional, Fallet, V., additional, Audigier-Valette, C., additional, Mezquita, L., additional, Calles, A., additional, Mountzios, G., additional, Tagliamento, M., additional, Raimbourg, J., additional, Terrisse, S., additional, Planchard, D., additional, Besse, B., additional, and Aldea, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
- Author
-
Abate, F, Todaro, M, van der Krogt, J-A, Boi, M, Landra, I, Machiorlatti, R, Tabbò, F, Messana, K, Abele, C, Barreca, A, Novero, D, Gaudiano, M, Aliberti, S, Di Giacomo, F, Tousseyn, T, Lasorsa, E, Crescenzo, R, Bessone, L, Ficarra, E, Acquaviva, A, Rinaldi, A, Ponzoni, M, Longo, D L, Aime, S, Cheng, M, Ruggeri, B, Piccaluga, P P, Pileri, S, Tiacci, E, Falini, B, Pera-Gresely, B, Cerchietti, L, Iqbal, J, Chan, W C, Shultz, L D, Kwee, I, Piva, R, Wlodarska, I, Rabadan, R, Bertoni, F, and Inghirami, G
- Published
- 2015
- Full Text
- View/download PDF
8. P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study
- Author
-
Bironzo, P., primary, Jacobs, F., additional, Cani, M., additional, Reale, M.L., additional, Tabbò, F., additional, Olmetto, E., additional, Capelletto, E., additional, Napoli, V., additional, Passiglia, F., additional, Listì, A., additional, Righi, L., additional, Di Maio, M., additional, Novello, S., additional, and Scagliotti, G., additional
- Published
- 2021
- Full Text
- View/download PDF
9. MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center
- Author
-
Bungaro, M., primary, Bertaglia, V., additional, Audisio, M., additional, Parlagreco, E., additional, Pisano, C., additional, Cetoretta, V., additional, Persano, I., additional, Jacobs, F., additional, Baratelli, C., additional, Consito, L., additional, Reale, M.L., additional, Tabbò, F., additional, Bironzo, P., additional, Scagliotti, G., additional, and Novello, S., additional
- Published
- 2021
- Full Text
- View/download PDF
10. 1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients
- Author
-
Mariniello, A., primary, Tabbò, F., additional, Indellicati, D., additional, Geuna, M., additional, Tesauro, M., additional, Rezmives, N.A., additional, Di Maio, M., additional, Bironzo, P., additional, Reale, M.L., additional, Passiglia, F., additional, Listi, A., additional, Capelletto, E., additional, Carnio, S., additional, Bertaglia, V., additional, Mecca, C., additional, Consito, L.T., additional, De Filippis, M., additional, Bungaro, M., additional, Paratore, C., additional, and Novello, S., additional
- Published
- 2021
- Full Text
- View/download PDF
11. 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer
- Author
-
Passiglia, F., primary, Tabbò, F., additional, Righi, L., additional, Bironzo, P., additional, Reale, M.L., additional, Listi, A., additional, Sini, C., additional, Vallone, S., additional, Arizio, F., additional, Secen, N.M., additional, Paz-Ares, L., additional, Felip, E., additional, Araújo, A., additional, Linardou, H., additional, Mohorcic, K., additional, Mazilu, L., additional, Szmytke, E., additional, Comanescu, A., additional, Scagliotti, G., additional, and Novello, S., additional
- Published
- 2021
- Full Text
- View/download PDF
12. 140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs
- Author
-
Reale, M.L., primary, Bironzo, P., additional, Righi, L., additional, Listi, A., additional, Tabbò, F., additional, Caglio, A., additional, Pisano, C., additional, Napoli, V.M., additional, Di Maio, M., additional, and Novello, S., additional
- Published
- 2021
- Full Text
- View/download PDF
13. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
- Author
-
Gobbini, E., primary, Chiari, R., additional, Pizzutillo, P., additional, Bordi, P., additional, Ghilardi, L., additional, Pilotto, S., additional, Osman, G., additional, Cappuzzo, F., additional, Cecere, F., additional, Riccardi, F., additional, Scotti, V., additional, Martelli, O., additional, Borra, G., additional, Maiello, E., additional, Rossi, A., additional, Graziano, P., additional, Gregorc, V., additional, Casartelli, C., additional, Sergi, C., additional, Del Conte, A., additional, Delmonte, A., additional, Bareggi, C., additional, Cortinovis, D., additional, Rizzo, P., additional, Tabbò, F., additional, Rossi, G., additional, Bria, E., additional, Galetta, D., additional, Tiseo, M., additional, Di Maio, M., additional, and Novello, S., additional
- Published
- 2019
- Full Text
- View/download PDF
14. P2.09-18 Lymphocyte Infiltration Pattern and STING Expression Identify Different Prognostic Groups in Early Stage NSCLC
- Author
-
Tabbò, F., primary, Guerrera, F., additional, Bironzo, P., additional, Gagliasso, M., additional, Cartia, C., additional, Rigutto, A., additional, Izzo, S., additional, Veneziano, F., additional, Arizio, F., additional, Ardissone, F., additional, Papotti, M., additional, Volante, M., additional, Novello, S., additional, and Righi, L., additional
- Published
- 2019
- Full Text
- View/download PDF
15. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
- Author
-
Skoulidis, F., primary, Arbour, K., additional, Hellmann, M., additional, Patil, P., additional, Marmarelis, M., additional, Owen, D., additional, Awad, M., additional, Murray, J., additional, Levy, B., additional, Hellyer, J., additional, Gainor, J., additional, Stewart, T., additional, Goldberg, S., additional, Dimou, A., additional, Bestvina, C., additional, Cummings, A., additional, Elamin, Y., additional, Lam, V., additional, Zhang, J., additional, Shu, C., additional, Riess, J., additional, Blakely, C., additional, Pecot, C., additional, Mezquita, L., additional, Tabbò, F., additional, Sacher, A., additional, Scheffler, M., additional, Ricciuti, B., additional, Venkatraman, D., additional, Rizvi, H., additional, Liu, C., additional, Johnston, R., additional, Ni, Y., additional, Azok, J., additional, Kier, M., additional, Katz, S., additional, Davies, K., additional, Segal, J., additional, Ritterhouse, L., additional, Shaish, H., additional, Lacroix, L., additional, Memmott, R., additional, Madrigal, J., additional, Goldman, J., additional, Lau, S., additional, Killam, J., additional, Walther, Z., additional, Carter, B., additional, Woodcock, M., additional, Roth, J., additional, Swisher, S., additional, Leighl, N., additional, Digumarthy, S., additional, Mooradian, M., additional, Rotow, J., additional, Wolf, J., additional, Scagliotti, G., additional, Planchard, D., additional, Besse, B., additional, Bivona, T., additional, Gandara, D., additional, Garon, E., additional, Rizvi, N., additional, Camidge, D.R., additional, Schalper, K., additional, Herbst, R., additional, Shaw, A., additional, Neal, J., additional, Wakelee, H., additional, Brahmer, J., additional, Jänne, P., additional, Carbone, D., additional, Aggarwal, C., additional, Pennell, N., additional, Rudin, C., additional, Papadimitrakopoulou, V., additional, and Heymach, J., additional
- Published
- 2019
- Full Text
- View/download PDF
16. P2.14-17 Correlation Between Clinic-Pathological Data and T790M Detection in EGFR Mutated NSCLC Patients Progressing on 1st/2nd Generation TKIs
- Author
-
Pignataro, D., primary, Tagliamento, M., additional, Reale, M.L., additional, Tabbò, F., additional, Bungaro, M., additional, Paratore, C., additional, Cetoretta, V., additional, De Filippis, M., additional, Bertaglia, V., additional, Passiglia, F., additional, Righi, L., additional, Bironzo, P., additional, and Novello, S., additional
- Published
- 2019
- Full Text
- View/download PDF
17. P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
- Author
-
Tabbò, F., primary, Gobbini, E., additional, Muscarella, L., additional, Rigutto, A., additional, Trombetta, D., additional, Bonfitto, A., additional, Galetta, D., additional, Maiello, E., additional, Martelli, O., additional, Tiseo, M., additional, Bordi, P., additional, Scotti, V., additional, Ghilardi, L., additional, Gregorc, V., additional, Sergi, C., additional, Pilotto, S., additional, Del Conte, A., additional, Cappuzzo, F., additional, Cortinovis, D., additional, Osman, G., additional, Bareggi, C., additional, Di Maio, M., additional, Rossi, A., additional, Rossi, G., additional, Bria, E., additional, Volante, M., additional, Scagliotti, G., additional, Graziano, P., additional, Novello, S., additional, and Righi, L., additional
- Published
- 2019
- Full Text
- View/download PDF
18. P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation
- Author
-
Bironzo, P., primary, Pignataro, D., additional, Audisio, M., additional, Tagliamento, M., additional, Paratore, C., additional, Tabbò, F., additional, Bungaro, M., additional, Zichi, C., additional, De Filippis, M., additional, Rapetti, S., additional, Cetoretta, V., additional, Carnio, S., additional, Mariniello, A., additional, Buffoni, L., additional, Lacidogna, G., additional, Di Maio, M., additional, and Novello, S., additional
- Published
- 2019
- Full Text
- View/download PDF
19. EP1.09-13 Clinic-Pathological and Molecular Features of PD-L1 Analyses in Advanced NSCLC: A Real Life Single Center Experience
- Author
-
Tabbò, F., primary, Righi, L., additional, Rota, G., additional, Cappia, S., additional, Rigutto, A., additional, Izzo, S., additional, Novello, S., additional, and Volante, M., additional
- Published
- 2019
- Full Text
- View/download PDF
20. P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy
- Author
-
Tabbò, F., primary, Annaratone, L., additional, Nocifora, A., additional, Vignale, C., additional, Carnio, S., additional, Metovic, J., additional, Veneziano, F., additional, Scodes, S., additional, Russo, A., additional, Franchina, T., additional, Sini, C., additional, Coco, S., additional, Garlatti, P., additional, Vieri, S., additional, Adamo, V., additional, Boccardo, S., additional, Grossi, F., additional, Cappuzzo, F., additional, Papotti, M., additional, Righi, L., additional, Passiglia, F., additional, and Novello, S., additional
- Published
- 2019
- Full Text
- View/download PDF
21. 74 (PB064) - Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions
- Author
-
Marinello, A., Vasseur, D., Conci, N., Lindsay, C., Metro, G., Ferrara, R., Eisert, A., Citarella, F., Fallet, V., Audugier-Valette, C., Cousin, S., Tabbò, F., Russo, A., Calles Blanco, A., Iranzo Gomez, P., Tagliamento, M., Mezquita, L., Ponce, S., Besse, B., and Aldea, M.
- Published
- 2022
- Full Text
- View/download PDF
22. P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma
- Author
-
Taulli, R., primary, Righi, L., additional, Tabbò, F., additional, Massa, F., additional, D'Aveni, A., additional, Morena, D., additional, Lingua, M.F., additional, Rigutto, A., additional, Napoli, F., additional, Picca, F., additional, Novello, S., additional, and Scagliotti, G., additional
- Published
- 2018
- Full Text
- View/download PDF
23. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1
- Author
-
Voena, C, primary, Di Giacomo, F, additional, Panizza, E, additional, D'Amico, L, additional, Boccalatte, F E, additional, Pellegrino, E, additional, Todaro, M, additional, Recupero, D, additional, Tabbò, F, additional, Ambrogio, C, additional, Martinengo, C, additional, Bonello, L, additional, Pulito, R, additional, Hamm, J, additional, Chiarle, R, additional, Cheng, M, additional, Ruggeri, B, additional, Medico, E, additional, and Inghirami, G, additional
- Published
- 2013
- Full Text
- View/download PDF
24. P-202 LUNG CANCER BIOBANKING: INTEGRATED APPROACH FOR PRECISION MEDICINE.
- Author
-
Guerrera, Francesco, Tabbò, F., Bessone, L., Di Gangi, S., Buffoni, L., Delsedime, L., Filosso, P.L., Oliaro, A., Ruffini, E., and Inghirami, G.
- Published
- 2014
- Full Text
- View/download PDF
25. 1343P Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%.
- Author
-
De Giglio, A., Zullo, L., Di Federico, A., Cani, M., Aldea, M., Favorito, V., Sadowska, A., Hendriks, L.E., Gorría Puga, T., Mezquita, L., Tabbò, F., Novello, S., Ardizzoni, A., Besse, B., and Gelsomino, F.
- Published
- 2024
- Full Text
- View/download PDF
26. 1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry.
- Author
-
Marinello, A., Massa, G., Rotow, J., Bote De Cabo, H., Monnet, I., Guisier, F., Duruisseaux, M., Benitez Montanez, J.C., Raimbourg, J., Costa, J., Tagliamento, M., Feng, J., Di Federico, A., Metro, G., Citarella, F., Tabbò, F., Lindsay, C., Iranzo Gomez, P., Besse, B., and Aldea, M.
- Published
- 2024
- Full Text
- View/download PDF
27. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
- Author
-
Thomas Tousseyn, Elena Lasorsa, M. Ponzoni, Cristina Abele, Andrea Acquaviva, S. A. Pileri, Pier Paolo Piccaluga, Domenico Novero, Maria Todaro, Antonella Barreca, Francesco Abate, Ivo Kwee, Giorgio Inghirami, F Di Giacomo, Javeed Iqbal, Indira Landra, Raul Rabadan, Silvio Aime, Wing C. Chan, Rodolfo Machiorlatti, Mangeng Cheng, Michela Boi, Enrico Tiacci, B Pera-Gresely, Francesco Bertoni, Leonard D. Shultz, J-A van der Krogt, Katia Messana, Bruce Ruggeri, Brunangelo Falini, Sabrina Aliberti, Fabrizio Tabbò, Marcello Gaudiano, Luca Bessone, Roberto Piva, R Crescenzo, Andrea Rinaldi, Iwona Wlodarska, Dario Livio Longo, Elisa Ficarra, Leandro Cerchietti, Abate, F., Todaro, M., Van Der Krogt, J.-A., Boi, M., Landra, I., Machiorlatti, R., Tabbò, F., Messana, K., Abele, C., Barreca, A., Novero, D., Gaudiano, M., Aliberti, S., Di Giacomo, F., Tousseyn, T., Lasorsa, E., Crescenzo, R., Bessone, L., Ficarra, E., Acquaviva, A., Rinaldi, A., Ponzoni, M., Longo, D.L., Aime, S., Cheng, M., Ruggeri, B., Piccaluga, P.P., Pileri, S., Tiacci, E., Falini, B., Pera-Gresely, B., Cerchietti, L., Iqbal, J., Chan, W.C., Shultz, L.D., Kwee, I., Piva, R., Wlodarska, I., Rabadan, R., Bertoni, F., Inghirami, G., The European T-cell Lymphoma Study Group [.., Agostinelli, C., ], European T-cell Lymphoma Study Group, Cavallo, F., Chiesa, N., Fienga, A., di Giacomo, F., Marchiorlatti, R., Martinoglio, B., Medico, E., Ferrero, GB., Mereu, E., Pellegrino, E., Scafò, I., Spaccarotella, E., Ubezzi, I., Urigu, S., Chiapella, A., Vitolo, U., Agnelli, L., Neri, A., Chilosi£££Anna Caliò Marco£££ AC., Zamó, A., Facchetti, F., Lonardi, S., De Chiara, A., Fulciniti, F., Ferreri, A., Piccaluga, PP., Van Loo, P., De Wolf-Peeters, C., Geissinger, E., Muller-Hermelink, HK., Rosenwald, A., Piris, MA., Rodriguez, ME., Chiattone, C., Paes, RA., Abate, F, Todaro, M, van der Krogt, Ja, Boi, M, Landra, I, Machiorlatti, R, Tabbò, F, Messana, K, Abele, C, Barreca, A, Novero, D, Gaudiano, M, Aliberti, S, Di Giacomo, F, Tousseyn, T, Lasorsa, E, Crescenzo, R, Bessone, L, Ficarra, E, Acquaviva, A, Rinaldi, A, Ponzoni, M, Longo, Dl, Aime, S, Cheng, M, Ruggeri, B, Piccaluga, Pp, Pileri, S, Tiacci, E, Falini, B, Pera-Gresely, B, Cerchietti, L, Iqbal, J, Chan, Wc, Shultz, Ld, Kwee, I, Piva, R, Wlodarska, I, Rabadan, R, Bertoni, F, Inghirami, G, and andThe European T-cell Lymphoma Study, Group
- Subjects
Pathology ,Cancer Research ,Lymphoma ,TRAF1 ,Messenger ,Drug Resistance ,Translocation, Genetic ,Fusion gene ,Mice ,Mice, Inbred NOD ,hemic and lymphatic diseases ,Tumor Cells, Cultured ,Anaplastic lymphoma kinase ,Anaplastic ,Anaplastic Lymphoma Kinase ,Anaplastic large-cell lymphoma ,Animals ,Blotting, Western ,Flow Cytometry ,Gene Expression Profiling ,High-Throughput Nucleotide Sequencing ,Humans ,Immunoprecipitation ,In Situ Hybridization, Fluorescence ,Lymphoma, Large-Cell, Anaplastic ,NF-kappa B ,Proteasome Inhibitors ,Proto-Oncogene Proteins c-myc ,RNA, Messenger ,Real-Time Polymerase Chain Reaction ,Receptor Protein-Tyrosine Kinases ,Repressor Proteins ,Reverse Transcriptase Polymerase Chain Reaction ,Signal Transduction ,TNF Receptor-Associated Factor 1 ,Tumor Suppressor Protein p53 ,Xenograft Model Antitumor Assays ,Drug Resistance, Neoplasm ,In Situ Hybridization ,Hematology ,Cultured ,Blotting ,Medicine (all) ,Large-Cell ,Tumor Cells ,Proteasome Inhibitor ,Receptor Protein-Tyrosine Kinase ,Oncology ,Western ,Human ,medicine.medical_specialty ,fusion detection tool ,Xenograft Model Antitumor Assay ,medicine.drug_class ,Translocation ,Anesthesiology and Pain Medicine ,Biology ,anaplastic large-cell lymphomas (ALCL) ,RNA-Seq data ,Fluorescence ,Article ,Genetic ,Internal medicine ,PRDM1 ,medicine ,traslocation ,Animal ,Repressor Protein ,medicine.disease ,ALK inhibitor ,anaplastic lymphoma kinase (ALK) ,Cancer research ,Inbred NOD ,RNA ,Neoplasm ,Positive Regulatory Domain I-Binding Factor 1 ,Lymphoma, Large-Cell, Anaplastic/drug therapy ,Lymphoma, Large-Cell, Anaplastic/genetics ,NF-kappa B/genetics ,NF-kappa B/metabolism ,Proteasome Inhibitors/pharmacology ,Proto-Oncogene Proteins c-myc/genetics ,Proto-Oncogene Proteins c-myc/metabolism ,RNA, Messenger/genetics ,Receptor Protein-Tyrosine Kinases/genetics ,Receptor Protein-Tyrosine Kinases/metabolism ,Repressor Proteins/genetics ,Repressor Proteins/metabolism ,TNF Receptor-Associated Factor 1/genetics ,TNF Receptor-Associated Factor 1/metabolism ,Translocation, Genetic/genetics ,Tumor Suppressor Protein p53/genetics ,Tumor Suppressor Protein p53/metabolism - Abstract
Although anaplastic large-cell lymphomas (ALCL) carrying anaplastic lymphoma kinase (ALK) have a relatively good prognosis, aggressive forms exist. We have identified a novel translocation, causing the fusion of the TRAF1 and ALK genes, in one patient who presented with a leukemic ALK+ ALCL (ALCL-11). To uncover the mechanisms leading to high-grade ALCL, we developed a human patient-derived tumorgraft (hPDT) line. Molecular characterization of primary and PDT cells demonstrated the activation of ALK and nuclear factor kappa B (NF kappa B) pathways. Genomic studies of ALCL-11 showed the TP53 loss and the in vivo subclonal expansion of lymphoma cells, lacking PRDM1/Blimp1 and carrying c-MYC gene amplification. The treatment with proteasome inhibitors of TRAF1-ALK cells led to the downregulation of p50/p52 and lymphoma growth inhibition. Moreover, a NF kappa B gene set classifier stratified ALCL in distinct subsets with different clinical outcome. Although a selective ALK inhibitor (CEP28122) resulted in a significant clinical response of hPDT mice, nevertheless the disease could not be eradicated. These data indicate that the activation of NF kappa B signaling contributes to the neoplastic phenotype of TRAF1-ALK ALCL. ALCL hPDTs are invaluable tools to validate the role of druggable molecules, predict therapeutic responses and implement patient specific therapies.
- Published
- 2015
28. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
- Author
-
Sílvia Beà, Michela Boi, Steven H. Swerdlow, Ken H. Young, Emanuele Zucca, Elias Campo, Andreas Rosenwald, Paola Bonetti, Pier Paolo Piccaluga, Thomas Tousseyn, Maria Todaro, András Matolcsy, Stefano Pileri, Socorro María Rodríguez-Pinilla, Govind Bhagat, Paola M.V. Rancoita, Maurilio Ponzoni, Miguel A. Piris, Botond Timár, Ivo Kwee, Roberto Piva, Reinhard Dummer, Fabrizio Tabbò, Andrea Rinaldi, Giorgio Inghirami, Francesco Bertoni, Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, Piva R, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F, Boi, M, Rinaldi, A, Kwee, I, Bonetti, P, Todaro, M, Tabbò, F, Piva, R, Rancoita, PAOLA MARIA VITTORIA, Matolcsy, A, Timar, B, Tousseyn, T, Rodríguez Pinilla, Sm, Piris, Ma, Beà, S, Campo, E, Bhagat, G, Swerdlow, Sh, Rosenwald, A, Ponzoni, Maurilio, Young, Kh, Piccaluga, Pp, Dummer, R, Pileri, S, Zucca, E, Inghirami, G, and Bertoni, F.
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Tumor suppressor gene ,Adolescent ,Immunology ,Biology ,Lymphoma, T-Cell ,Biochemistry ,Pathogenesis ,Mice ,Young Adult ,Mice, Inbred NOD ,hemic and lymphatic diseases ,Cell Line, Tumor ,PRDM1 ,medicine ,Anaplastic lymphoma kinase ,T-cell lymphoma ,Animals ,Humans ,Anaplastic Lymphoma Kinase ,Anaplastic large-cell lymphoma ,Aged ,Aged, 80 and over ,Large cell ,Receptor Protein-Tyrosine Kinases ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Lymphoma ,Gene Expression Regulation, Neoplastic ,Repressor Proteins ,Cancer research ,Lymphoma, Large-Cell, Anaplastic ,Female ,Positive Regulatory Domain I-Binding Factor 1 ,Tumor Suppressor Protein p53 ,Neoplasm Transplantation - Abstract
Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma that can present as a systemic or primary cutaneous disease. Systemic ALCL represents 2% to 5% of adult lymphoma but up to 30% of all pediatric cases. Two subtypes of systemic ALCL are currently recognized on the basis of the presence of a translocation involving the anaplastic lymphoma kinase ALK gene. Despite considerable progress, several questions remain open regarding the pathogenesis of both ALCL subtypes. To investigate the molecular pathogenesis and to assess the relationship between the ALK(+) and ALK(-) ALCL subtypes, we performed a genome-wide DNA profiling using high-density, single nucleotide polymorphism arrays on a series of 64 cases and 7 cell lines. The commonest lesions were losses at 17p13 and at 6q21, encompassing the TP53 and PRDM1 genes, respectively. The latter gene, coding for BLIMP1, was inactivated by multiple mechanisms, more frequently, but not exclusively, in ALK(-)ALCL. In vitro and in vivo experiments showed that that PRDM1 is a tumor suppressor gene in ALCL models, likely acting as an antiapoptotic agent. Losses of TP53 and/or PRDM1 were present in 52% of ALK(-)ALCL, and in 29% of all ALCL cases with a clinical implication.
- Published
- 2013
29. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma
- Author
-
Giovannino Ciccone, Francesca Maletta, Anna Sapino, Pier Luigi Filosso, Nicola Veronese, Francesco Guerrera, Alberto Oliaro, Fabrizio Tabbò, Marcello Gaudiano, Claudio Luchini, Enrico Ruffini, Giorgio Inghirami, Luisa Delsedime, Licia Montagna, Filomena Di Giacomo, Alessia Nottegar, Aldo Scarpa, Marco Chilosi, Enrica Migliore, Tabbò, F., Nottegar, A., Guerrera, F., Migliore, E., Luchini, C., Maletta, F., Veronese, N., Montagna, L., Gaudiano, M., Di Giacomo, F., Filosso, P.L., Delsedime, L., Ciccone, G., Scarpa, A., Sapino, A., Oliaro, A., Ruffini, E., Inghirami, G., and Chilosi, M.
- Subjects
Lung adenocarcinoma ,Morphology ,Adult ,Male ,0301 basic medicine ,Oncology ,Biomarkers ,Genetic mutations ,Immunohistochemistry ,Survival analysis ,Pathology ,medicine.medical_specialty ,Candidate gene ,Cell of origin ,six-immunohistochemical markers panel (TTF1, SP-A, Napsin A, MUC5AC, CDX2 and CK5) ,Adenocarcinoma of Lung ,Kaplan-Meier Estimate ,genetic mutations ,Gene mutation ,Biology ,medicine.disease_cause ,adenocarcinoma (ADC) ,survival analysis ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,morphology ,Biomarkers, Tumor ,medicine ,Humans ,CDX2 ,Aged ,biomarkers ,immunohistochemistry ,lung adenocarcinoma ,Middle Aged ,respiratory system ,Prognosis ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Female ,KRAS - Abstract
Strong prognostic markers able to stratify lung adenocarcinoma (ADC) patients are lacking. We evaluated whether a six-immunohistochemical markers panel (TTF1, SP-A, Napsin A, MUC5AC, CDX2 and CK5), defining the putative neoplastic “cell of origin,” allows to identify prognostic subgroups among lung ADC. We screened a large cohort of ADC specimens (2003–2013) from Torino Institutional Repository identifying: (i) marker positivity by immunohistochemistry, (ii) main morphological appearance by light microscopy, (iii) presence of “hotspot” mutations of candidate genes by Sequenom technology. To evaluate possible predictors of survival and time to recurrence, uni- and multivariable-adjusted comparisons were performed. We identified 4 different subgroups: “alveolar,” “bronchiolar,” “mixed” and “null type." Alveolar-differentiated ADC were more common in young (P =.065), female (P =.083) patients, frequently harboring EGFR-mutated (P =.003) tumors with acinar pattern (P
- Published
- 2018
30. Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis
- Author
-
Antonio Pea, Monica Cheng, Matteo Fassan, Fabio Bagante, Takuma Kaneko, Nicola Veronese, Camilla Pilati, M. Infante, Fabrizio Tabbò, Aldo Scarpa, Brendon Stubbs, Claudio Luchini, Jacopo Demurtas, Alessia Nottegar, Liang Cheng, Luchini, C., Veronese, N., Nottegar, A., Cheng, M., Kaneko, T., Pilati, C., Tabbò, F., Stubbs, B., Pea, A., Bagante, F., Demurtas, J., Fassan, M., Infante, M., Cheng, L., and Scarpa, A.
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Extracapsular ,Extranodal ,Lung cancer ,Metastasis ,NSCLC ,Prognosis ,TNM staging system ,Malignancy ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,030212 general & internal medicine ,Molecular Biology ,Ene reaction ,Lung cancer . NSCLC . Prognosis . Extranodal . Extracapsular . Metastasis ,business.industry ,Hazard ratio ,Retrospective cohort study ,Cell Biology ,General Medicine ,medicine.disease ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Relative risk ,Lymph Nodes ,Neoplasm Recurrence, Local ,business - Abstract
Extranodal extension (ENE) of nodal metastasis is defined as the extension of metastatic cells through the nodal capsule into the perinodal tissue. This morphological parameter, recently proposed as an important prognostic factor in different types of malignancy, has not been included in the TNM staging system for non-small cell lung cancer (NSCLC). In this systematic review with meta-analysis, we weighted the prognostic role of ENE in patients with lymph node-positive NSCLC. Two independent authors searched SCOPUS and PubMed through 28 February 2017. Prospective and retrospective studies on NSCLC, comparing patients with presence of ENE (ENE+) ENE+) vs. only intranodal extension (ENE–) and including data regarding prognosis, were considered as eligible. Data were summarized using risk ratios (RR) for the number of deaths/recurrences, and hazard ratios (HR) with 95% confidence intervals (CI) for time-dependent risk related to ENE+, adjusted for potential confounders. We identified 13 studies, including 1709 patients (573 ENE+ and 1136 ENE–) with a median follow-up of 60months. ENE was associated with a significantly increased risk of mortality of all causes (RR = 1.39, 95% CI: 1.18–1.65, P < 0.0001, I2= 70%; HR = 1.30, 95% CI: 1.01–1.67, P = 0.04, I2= 0%) and of disease recurrence (RR = 1.32, 95% CI: 1.04–1.68, P = 0.02, I2= 42%; HR = 1.93, 95% CI: 1.53–2.44, P < 0.0001, I2= 0%). We conclude that in NSCLC, requirements for assessment of ENE should be included in gross sampling and ENE status should be included in the pathology report. Inclusion of ENE status in oncology staging systems will allow further assessment of its role as prognostic parameter. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
- Published
- 2018
31. Genetics of Follicular Lymphoma Transformation
- Author
-
Maurilio Ponzoni, Antony B. Holmes, Sami N. Malek, Laura Pasqualucci, Amy Chadburn, Vladimir Trifonov, Fabrizio Tabbò, Davide Rossi, Vundavalli V. Murty, Giorgio Inghirami, Govind Bhagat, Mansi Vasishtha, Peter Ouillette, Monica Messina, Gianluca Gaidano, Hossein Khiabanian, Riccardo Dalla-Favera, Raul Rabadan, Marco Fangazio, Pasqualucci, L, Khiabanian, H, Fangazio, M, Vasishtha, M, Messina, M, Holmes, Ab, Ouillette, P, Trifonov, V, Rossi, D, Tabbò, F, Ponzoni, Maurilio, Chadburn, A, Murty, Vv, Bhagat, G, Gaidano, G, Inghirami, G, Malek, Sn, Rabadan, R, and Dalla Favera, R.
- Subjects
Carcinogenesis ,Genes, myc ,Follicular lymphoma ,Somatic hypermutation ,Apoptosis ,Biology ,medicine.disease_cause ,Article ,General Biochemistry, Genetics and Molecular Biology ,Epigenesis, Genetic ,Evolution, Molecular ,CDKN2A ,medicine ,Genetics ,Humans ,Lymphoma, Follicular ,lcsh:QH301-705.5 ,Mutation ,Genes, p16 ,Germinal center ,Genomics ,Genes, p53 ,medicine.disease ,lcsh:Biology (General) ,FOS: Biological sciences ,Cancer research ,Lymphomas ,Clone (B-cell biology) ,Diffuse large B-cell lymphoma - Abstract
SummaryFollicular lymphoma (FL) is an indolent disease, but 30%–40% of cases undergo histologic transformation to an aggressive malignancy, typically represented by diffuse large B cell lymphoma (DLBCL). The pathogenesis of this process remains largely unknown. Using whole-exome sequencing and copy-number analysis, we show here that the dominant clone of FL and transformed FL (tFL) arise by divergent evolution from a common mutated precursor through the acquisition of distinct genetic events. Mutations in epigenetic modifiers and antiapoptotic genes are introduced early in the common precursor, whereas tFL is specifically associated with alterations deregulating cell-cycle progression and DNA damage responses (CDKN2A/B, MYC, and TP53) as well as aberrant somatic hypermutation. The genomic profile of tFL shares similarities with that of germinal center B cell-type de novo DLBCL but also displays unique combinations of altered genes with diagnostic and therapeutic implications.
- Published
- 2014
32. Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology
- Author
-
Fabrizio Tabbò, Antonio Santo, Sara Cingarlini, Eliana Gilioli, Licia Montagna, Marco Chilosi, Claudio Doglioni, Serena Pedron, Matteo Brunelli, Albino Eccher, Alessia Nottegar, Claudio Luchini, Emilio Bria, Nicola Veronese, Giorgio Inghirami, Maria Giulia Cangi, Chiara Ogliosi, Nottegar, A., Tabbo, F., Luchini, C., Brunelli, M., Bria, E., Veronese, N., Santo, A., Cingarlini, S., Gilioli, E., Ogliosi, C., Eccher, A., Montagna, L., Pedron, S., Doglioni, C., Cangi, M. G., Inghirami, G., Chilosi, M., Tabbò, F., and Cangi, M.G.
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Histology ,intestinal-type adenocarcinoma ,Cellular differentiation ,DNA Mutational Analysis ,Thyroid Nuclear Factor 1 ,Adenocarcinoma ,Biology ,medicine.disease_cause ,Pathology and Forensic Medicine ,Metastasis ,Diagnosis, Differential ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,0302 clinical medicine ,KRAS ,Biomarkers, Tumor ,medicine ,Humans ,CDX2 Transcription Factor ,Pathology, Molecular ,enteric, lung adenocarcinoma, intestinal-type adenocarcinoma, CDX-2, CDX2, KRAS ,Lung ,Keratin-7 ,enteric ,Cancer ,Cell Differentiation ,Pulmonary adenocarcinoma with enteric differentiation (PAED) ,lung adenocarcinoma ,medicine.disease ,CDX-2 ,Immunohistochemistry ,Medical Laboratory Technology ,030104 developmental biology ,medicine.anatomical_structure ,CDX2 ,Alveolar Epithelial Cells ,030220 oncology & carcinogenesis ,Mutation ,Differential diagnosis ,Colorectal Neoplasms - Abstract
Pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare subtype of lung adenocarcinoma recently recognized in the WHO classification. It is defined as an adenocarcinoma in which the enteric component exceeds 50% and have to show the expression of at least 1 immunohistochemical marker of enteric differentiation. Although the definition of this tumor type is very important, above all in the differential diagnosis between a primary lung tumor and a metastasis of colorectal adenocarcinoma, this cancer still lacks a distinctive immunohistochemical and molecular signature. We recruited the largest series in the literature of PAEDs according to the morphology and the positivity for intestinal markers. Then, we evaluated the immunohistochemical and molecular profile of these adenocarcinomas. In our series, CDX-2 and CK7 were the immunohistochemical markers mostly expressed by PAEDs. There was an inverse relationship between the expression of pnuemocytes markers, such as TTF-1, and intestinal markers. Molecular analysis revealed KRAS as the most frequently mutated gene (>60% of cases), with very few cases harboring abnormalities affecting EGFR, BRAF, and ALK genes. PAEDs are morphologically very heterogenous. The immunohistochemical profile based on CDX-2 and CK7 positivity of PAEDs appears very robust to support this diagnosis, and it is applicable also on small biopsies. KRAS appears as the most important mutated gene in such tumors. © 2016 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2016
33. Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma
- Author
-
Tabbo', Fabrizio, Maurilio, Ponzoni, Raul, Rabadan, Francesco, Bertoni, Inghirami, Giorgio, cell Lymphoma Study Group, European T., Tabbò, F, Ponzoni, Maurilio, Rabadan, R, Bertoni, F, and Inghirami, G.
- Subjects
CD30 ,Somatic cell ,Large cell ,Receptor Protein-Tyrosine Kinases ,Hematology ,Biology ,medicine.disease ,hemic and lymphatic diseases ,medicine ,Cancer research ,Anaplastic lymphoma kinase ,Signal transduction ,Anaplastic large-cell lymphoma ,Signalling pathways - Abstract
Purpose of reviewAnaplastic large cell lymphomas (ALCLs) are rare entities whose somatic genetic lesions have been identified only in a subset of patients. Thus, an integrated and massive discovery programme is required to define their tumourigenic alterations and to design more successful tailored
- Published
- 2013
34. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
- Author
-
Carmela Ciardullo, Sara Monti, Riccardo Dalla-Favera, Valter Gattei, Silvia Deaglio, Laura Pasqualucci, Daniela Piranda, Luca Arcaini, Vladimir Trifonov, Claudio Agostinelli, Giulia Fabbri, Fabio Facchetti, Silvia Rasi, Rosella Famà, Giorgio Inghirami, Pier Paolo Piccaluga, Gianluca Gaidano, Antony B. Holmes, Jiguang Wang, Clara Deambrogi, Roberto Serra, Francesco Bertoni, Mariangela Greco, Davide Rossi, Marco Fangazio, Fabrizio Tabbò, Andrea Rinaldi, Marco Lucioni, Robin Foà, Tiziana Vaisitti, Roberto Marasca, Raul Rabadan, Giulia Daniele, Stefania Cresta, Monica Messina, Francesca Arruga, Stefano Pileri, Alessio Bruscaggin, Silvia Franceschetti, Valeria Spina, Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R, Pasqualucci L, Rabadan R, and Gaidano G.
- Subjects
endocrine system diseases ,medicine.disease_cause ,0302 clinical medicine ,NOTCH2 ,immune system diseases ,hemic and lymphatic diseases ,Immunology and Allergy ,Exome ,Receptor, Notch2 ,Receptor, Notch1 ,notch2 ,next generation sequencing ,0303 health sciences ,Mutation ,B-Lymphocytes ,NF-kappa B ,Nuclear Proteins ,RNA-Binding Proteins ,Marginal zone ,DNA-Binding Proteins ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Splenic Marginal Zone Lymphoma ,Signal Transduction ,endocrine system ,Lymphoma, B-Cell ,Immunology ,Notch signaling pathway ,splenic marginal zone lymphoma ,Lymphoproliferative disorders ,Biology ,Polymorphism, Single Nucleotide ,Article ,03 medical and health sciences ,medicine ,Humans ,Splenic marginal zone lymphoma ,B cell ,030304 developmental biology ,Homeodomain Proteins ,Splenic Neoplasms ,medicine.disease ,Chromatin Assembly and Disassembly ,Lymphoma ,next generation-sequencing ,Cancer research - Abstract
Notch2 mutations represent the most frequent lesion in splenic marginal zone lymphoma., Splenic marginal zone lymphoma (SMZL) is a B cell malignancy of unknown pathogenesis, and thus an orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis, we show that the SMZL exome carries at least 30 nonsilent gene alterations. Mutations in NOTCH2, a gene required for marginal-zone (MZ) B cell development, represent the most frequent lesion in SMZL, accounting for ∼20% of cases. All NOTCH2 mutations are predicted to cause impaired degradation of the NOTCH2 protein by eliminating the C-terminal PEST domain, which is required for proteasomal recruitment. Among indolent B cell lymphoproliferative disorders, NOTCH2 mutations are restricted to SMZL, thus representing a potential diagnostic marker for this lymphoma type. In addition to NOTCH2, other modulators or members of the NOTCH pathway are recurrently targeted by genetic lesions in SMZL; these include NOTCH1, SPEN, and DTX1. We also noted mutations in other signaling pathways normally involved in MZ B cell development, suggesting that deregulation of MZ B cell development pathways plays a role in the pathogenesis of ∼60% SMZL. These findings have direct implications for the treatment of SMZL patients, given the availability of drugs that can target NOTCH, NF-κB, and other pathways deregulated in this disease.
- Published
- 2012
35. Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer.
- Author
-
Centonza A, Mazza T, Trombetta D, Sparaneo A, Petrizzelli F, Castellana S, Centra F, Fabrizio FP, Di Micco CM, Benso F, Tabbò F, Righi L, Merlini A, Graziano P, and Muscarella LA
- Abstract
Anaplastic lymphoma kinase (ALK) fusions account for 5-7% of non-small cell lung cancer (NSCLC) patients, the therapeutic approaches for which have significantly evolved in the last few years. However, the response to target therapies remains heterogeneous, partially due to the many different ALK fusion variants reported to date. Rare fusion variants have also been discovered, but their role in influencing responses to ALK inhibitors (ALKis) remains poorly elucidated. Laboratory investigation at both the tissue and protein levels, and a molecular profile by next-generation sequencing (NGS) were performed on a lung biopsy sample from one patient with poorly differentiated adenocarcinoma. An in silico prediction model using ColabFold software v1.5.5 was used to model and predict the entire structure of the chimeric aberrant ALK protein. Here, we report a case of a former smoker, a 60-year-old man, diagnosed with NSCLC and undergoing ALK translocation. He received first-, second- and third-generation ALK protein inhibitors (ALKis), showing a clinical benefit for about 4 years. IHC analysis and the molecular examination of the tissue biopsy indicated a positive staining for ALK and a novel ALK gene fusion variant, involving the sperm antigen with calponin homology and coiled-coil domain 1-like (SPECC1L) gene with an unreported breakpoint in exon 7. The novel SPECCL1::ALK fusion was identified using Anchored Multiplex PCR (AMP)-NGS technology and was predicted to retain the Pkinase_Tyr domain at the carboxy-terminal region of the resulting chimeric protein. To the best of our knowledge, this is the first case of an ALK-positive NSCLC patient carrying the SPECC1L exon 7 fusion breakpoint and one of the few reports about clinical outcomes related to SPECC1L::ALK fusion. The in silico hypothesized biological role of this newly identified fusion variant corroborates the observed clinical response to multiple ALKis. The molecular findings also reinforce the utility of AMP-based NGS technology as a valuable tool for the identification of rare chromosomal events that may be related to the variability of patient outcomes to different ALKis treatments.
- Published
- 2024
- Full Text
- View/download PDF
36. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase ( ALK ) rearrangements and co-existing alterations-a retrospective cohort study.
- Author
-
Li J, Huang K, Ji H, Qian J, Lu H, Zhang Y, Russo A, Romero A, Urbanska EM, Tabbò F, Zhao X, and Chu T
- Abstract
Background: Alectinib significantly improves survival of non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase ( ALK )-rearrangement. In this study, we analyzed the effects of different ALK rearrangements and co-mutations on the efficacy of alectinib., Methods: Using the electronic medical record system, we reviewed in terms of clinical and pathological features patients with advanced (IIIB/IV stage) ALK -rearranged NSCLC at Shanghai Chest Hospital between January 2018 and December 2021 who were treated with alectinib in first or second line and were assessed for objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)., Results: A total of 66 patients were enrolled in the study, and 17 types of ALK rearrangements were detected, of which five types of ALK rearrangements responded well to alectinib. We classified ALK -rearrangements into four main types, namely echinoderm microtubule-associated protein-like 4 ( EML4 )- ALK (E6:A20), EML4-ALK (E13:A20), EML4-ALK (E20:A20), and others. There was no significant difference in ORR and DCR of these types (ORR: 31.3% vs. 13.0% vs. 18.2% vs. 17.6%, P=0.575; DCR: 93.8% vs. 95.6% vs. 100.0% vs. 88.2%, P=0.627). The 3-year PFS rates were 25.0% (4/16) vs. 13.0% (3/23) vs. 27.3% (3/11) vs. 18.8% (3/16) for EML4-ALK (E6:A20), EML4-ALK (E13:A20), EML4-ALK (E20:A20), and others, respectively (P=0.725). The results of co-mutation analysis showed that the median PFS (mPFS) for patients with tumors harboring TP53 mutations was 30.4 months, significantly shorter than that of patients with tumors without co-mutations and whose mPFS was not mature (P=0.026). TSC1 co-mutation was also identified as a detrimental factor in outcome, with a DCR of 60% vs. 100% (P=0.031), mPFS of 30.4 months vs. not applicable (P=0.160) in patients with vs. those without this co-mutation, respectively. The efficacy of alectinib in patients with brain metastases is comparable to that in patients without distant organ metastases. There were two cases with specific fusion types that also responded to alectinib; namely, double ALK -rearrangements: EML4-ALK (E13:A20) and MSH2-ALK (M7:A20), and with a rare fusion partner, SPECC1L-ALK (S8:A20). Their PFS were 8.7 and 38.0 months, respectively., Conclusions: In this study, the efficacy of alectinib in different types of ALK -rearrangements varied slightly. TP53 and TSC1 co-mutations were identified as detrimental factors affecting efficacy. This study provides references for the response to alectinib in patients with different types of ALK rearrangements and co-mutation., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-658/coif). Y.Z. and X.Z. are from 3D Medicines Inc., Shanghai, China. A.R. has received advisory board honoraria from AstraZeneca, MSD, Novartis, Pfizer, BMS, and Amgen; writing engagement honoraria from AstraZeneca, MSD, Roche and Novartis; speaker bureau from AstraZeneca and BMS. A.R. reports research funding from EMQN, GECP; consulting fees from AstraZeneca; payment or honoraria for lectures, presentations, speaker bureaus from Thermofisher Scientific, Illumina, Health in code; and travel expenses from Thermofisher Scientific, Bristol Myers Squibb Foundation, Takeda. She also serves as advisory board member in Takeda. E.M.U. reports honoraria for lectures from Amgen, AstraZeneca, Janssen, Novartis; support from AstraZeneca for participation at IASLC WCLC 2023, Singapore, and advisory board member in Pfizer, Roche, Takeda. The other authors have no conflicts of interest to declare., (2023 Translational Lung Cancer Research. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
37. Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
- Author
-
Anobile DP, Salaroglio IC, Tabbò F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E, Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, and Riganti C
- Subjects
- Humans, Female, Male, Animals, Mice, Receptors, Estrogen metabolism, Immune Checkpoint Inhibitors therapeutic use, Estrogen Receptor alpha genetics, B7-H1 Antigen antagonists & inhibitors, Estradiol pharmacology, Estradiol therapeutic use, Estrogens, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Antineoplastic Agents, Immunological therapeutic use
- Abstract
Purpose: The response to immune checkpoint inhibitors (ICI) often differs between genders in non-small cell lung cancer (NSCLC), but metanalyses results are controversial, and no clear mechanisms are defined. We aim at clarifying the molecular circuitries explaining the differential gender-related response to anti-PD-1/anti-PD-L1 agents in NSCLC., Experimental Design: We prospectively analyzed a cohort of patients with NSCLC treated with ICI as a first-line approach, and we identified the molecular mechanisms determining the differential efficacy of ICI in 29 NSCLC cell lines of both genders, recapitulating patients' phenotype. We validated new immunotherapy strategies in mice bearing NSCLC patient-derived xenografts and human reconstituted immune system ("immune-PDXs")., Results: In patients, we found that estrogen receptor α (ERα) was a predictive factor of response to pembrolizumab, stronger than gender and PD-L1 levels, and was directly correlated with PD-L1 expression, particularly in female patients. ERα transcriptionally upregulated CD274/PD-L1 gene, more in females than in males. This axis was activated by 17-β-estradiol, autocrinely produced by intratumor aromatase, and by the EGFR-downstream effectors Akt and ERK1/2 that activated ERα. The efficacy of pembrolizumab in immune-PDXs was significantly improved by the aromatase inhibitor letrozole, which reduced PD-L1 and increased the percentage of antitumor CD8+T-lymphocytes, NK cells, and Vγ9Vδ2 T-lymphocytes, producing durable control and even tumor regression after continuous administration, with maximal benefit in 17-β-estradiol/ERα highfemale immune-xenografts., Conclusions: Our work unveils that 17-β-estradiol/ERα status predicts the response to pembrolizumab in patients with NSCLC. Second, we propose aromatase inhibitors as new gender-tailored immune-adjuvants in NSCLC. See related commentary by Valencia et al., p. 3832., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
38. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
- Author
-
Normanno N, De Luca A, Abate RE, Morabito A, Milella M, Tabbò F, Curigliano G, Masini C, Marchetti P, Pruneri G, Guarneri V, Frassineti GL, Fasola G, Adamo V, Daniele B, Berardi R, Feroce F, Maiello E, and Pinto C
- Subjects
- Humans, Mutation, Genomics, High-Throughput Nucleotide Sequencing, Bile Ducts, Intrahepatic pathology, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms pathology, Bile Duct Neoplasms
- Abstract
Background: The Italian Register of Actionable Mutations (RATIONAL) is a multicentric, observational study collecting next-generation sequencing (NGS)-based tumour profiling data of patients with advanced solid tumours., Methods: The study enrols patients who had available an NGS-based tumour profiling (Pathway-A) or undergo comprehensive genomic profiling (CGP) with FoundationOne CDx assays within the trial (Pathway-B). The primary endpoint was the rate of actionable mutations identified., Results: Sequencing data were available for 738 patients in Pathway-A (218) and -B (520). In Pathway-A, 154/218 (70.6%) tests were performed using NGS panels ≤52 genes, and genomic alterations (GAs) were found in 164/218 (75.2%) patients. In Pathway-B, CGP revealed GAs in 512/520 (98.5%) patients. Levels I/II/III actionable GAs according to the European Society of Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT) were identified in 254/554 (45.8%) patients with non-small-cell lung cancer, cholangiocarcinoma, colorectal, gastric, pancreatic and breast cancer. The rate of patients with level I GAs was similar in Pathways A and B (69 versus 102). CGP in Pathway-B revealed a higher number of patients with level II/III GAs (99 versus 20) and potentially germline pathogenic/likely pathogenic variants (58 versus 15) as compared with standard testing in Pathway-A. In patients with cancer of unknown primary, CGP detected OncoKB levels 3B/4 GAs in 31/58 (53.4%) cases. Overall, 67/573 (11.7%) of patients received targeted therapy based on genomic testing., Conclusion: The Italian Register of Actionable Mutations represents the first overview of genomic profiling in Italian current clinical practice and highlights the utility of CGP for identifying therapeutic targets in selected cancer patients., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: N. Normanno declares: speaker’s fee and/or advisory boards from MSD, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermofisher, AstraZeneca, Eli Lilly; financial support to research projects (institutional grants) from Merck, Thermofisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina; non-financial interests President of the International Quality Network for Pathology (IQN Path) and Past President of the Italian Cancer Society (SIC). G. Curigliano declares: speaker’s fee/consulting fees/travel support from BMS, Roche, Pfizer, Novartis, Lilly, AstraZeneca, Daichii Sankyo, Merck, Seagen, Ellipsis, Gilead, Pfizer, Relay. V. Guarneri declares: speaker’s fee/consulting fees/travel support from EliLilly, Amgen, GSK, Gilead, AstraZeneca, Eisai, Exact Sciences, Merck Serono, MSD, Novartis, Olema Oncology, Sanofi. V. Adamo declares: speaker’s fee/consulting fees/travel support from Pfizer, MSD, Amgen, BMS, Novartis, AstraZeneca, Lilly. G. L. Frassineti declares: speaker’s fee/consulting fees/travel support from Servier, Merck, Bayer, MSD. B. Daniele declares: speaker’s fee/consulting fees/travel support from EISAI, Ipsen, AstraZeneca, ROCHE, Amgen, MSD, Sanofi. A. Morabito declares: speaker’s fee/consulting fees/travel support from Roche, MSD, AstraZeneca, Novartis, Boehringer, Lilly, Takeda, BMS, Pfizer. G. Fasola declares: speaker’s fee/consulting fees/travel support from Servier, Asytazeneca, Eubea, VyvaMed, MI&T, A&G, GSK, BMS, Merck, Ipsen. Roche, F. Tabbò declares: speaker’s fee/consulting fees/travel support from Roche, AstraZeneca. Takeda, C. Masini declares consulting fees from BMS, Astellas, Janssen, MSD, Ipsen. C. Pinto declares personal fees from Amgen, Astellas, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier, A. De Luca declares no conflict of interest. R. Esposito Abate declares no conflict of interest. M. Milella declares grants or contracts from Roche and Novartis, payment for consulting fees from Viatris, AstraZeneca, MSD, and Merck; payment for participation on a Data Safety Monitoring Board or Advisory Board from Novartis. P. Marchetti PM declares consultant/advisory role for BMS, Roche, Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. G. Pruneri declares honoraria from Novartis, Roche, Lilly and Exact Science. R. Berardi declares consultant/advisory board activities for AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli-Lilly, Roche. F. Feroce declares no conflict of interest. E. Maiello declares no conflict of interest., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
39. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
- Author
-
Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, Ambrogio C, Germena G, Martinengo C, Peola S, Mota I, Vissio E, Molinaro L, Arigoni M, Olivero M, Calogero R, Prokoph N, Tabbò F, Shoji B, Brugieres L, Geoerger B, Turner SD, Cuesta-Mateos C, D'Aliberti D, Mologni L, Piazza R, Gambacorti-Passerini C, Inghirami GG, Chiono V, Kamm RD, Hirsch E, Koch R, Weinstock DM, Aster JC, Voena C, and Chiarle R
- Subjects
- Humans, Animals, Mice, Crizotinib pharmacology, Crizotinib therapeutic use, Receptor Protein-Tyrosine Kinases metabolism, Anaplastic Lymphoma Kinase, Receptors, CCR7 genetics, Tyrosine Kinase Inhibitors, Endothelial Cells metabolism, Phosphatidylinositol 3-Kinases, Protein-Tyrosine Kinases, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Cell Line, Tumor, Tumor Microenvironment, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Lymphoma, Large-Cell, Anaplastic drug therapy, Lymphoma, Large-Cell, Anaplastic genetics, Lymphoma, Large-Cell, Anaplastic pathology
- Abstract
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been studied extensively in ALK-driven non-small cell lung cancer, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL). Here, we identify a survival pathway supported by the tumor microenvironment that activates phosphatidylinositol 3-kinase γ (PI3K-γ) signaling through the C-C motif chemokine receptor 7 (CCR7). We found increased PI3K signaling in patients and ALCL cell lines resistant to ALK TKIs. PI3Kγ expression was predictive of a lack of response to ALK TKI in patients with ALCL. Expression of CCR7, PI3Kγ, and PI3Kδ were up-regulated during ALK or STAT3 inhibition or degradation and a constitutively active PI3Kγ isoform cooperated with oncogenic ALK to accelerate lymphomagenesis in mice. In a three-dimensional microfluidic chip, endothelial cells that produce the CCR7 ligands CCL19/CCL21 protected ALCL cells from apoptosis induced by crizotinib. The PI3Kγ/δ inhibitor duvelisib potentiated crizotinib activity against ALCL lines and patient-derived xenografts. Furthermore, genetic deletion of CCR7 blocked the central nervous system dissemination and perivascular growth of ALCL in mice treated with crizotinib. Thus, blockade of PI3Kγ or CCR7 signaling together with ALK TKI treatment reduces primary resistance and the survival of persister lymphoma cells in ALCL.
- Published
- 2023
- Full Text
- View/download PDF
40. Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC.
- Author
-
Malapelle U, Tabbò F, and Muscarella LA
- Abstract
Competing Interests: UM has received personal fees as consultant and/or speaker bureau from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis, and Hedera, for work performed outside of the current study. FT has received personal fees as speaker bureau/honoraria from AstraZeneca, Roche, Novartis, Takeda for work performed outside of the current study. LAM has received personal fees as speaker bureau/honoraria from Qbgroup, Diatech Pharmacogenetics, ElmaResearch and AstraZeneca for work performed outside of the current study.
- Published
- 2023
- Full Text
- View/download PDF
41. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.
- Author
-
Bersani F, Picca F, Morena D, Righi L, Napoli F, Russo M, Oddo D, Rospo G, Negrino C, Castella B, Volante M, Listì A, Zambelli V, Benso F, Tabbò F, Bironzo P, Monteleone E, Poli V, Pietrantonio F, Di Nicolantonio F, Bardelli A, Ponzetto C, Novello S, Scagliotti GV, and Taulli R
- Subjects
- Humans, Biomarkers, Computational Biology, RNA genetics, RNA metabolism, Neoplasms genetics, RNA, Circular genetics
- Abstract
Background: MET-driven acquired resistance is emerging with unanticipated frequency in patients relapsing upon molecular therapy treatments. However, the determination of MET amplification remains challenging using both standard and next-generation sequencing-based methodologies. Liquid biopsy is an effective, non-invasive approach to define cancer genomic profiles, track tumor evolution over time, monitor treatment response and detect molecular resistance in advance. Circular RNAs (circRNAs), a family of RNA molecules that originate from a process of back-splicing, are attracting growing interest as potential novel biomarkers for their stability in body fluids., Methods: We identified a circRNA encoded by the MET gene (circMET) and exploited blood-derived cell-free RNA (cfRNA) and matched tumor tissues to identify, stratify and monitor advanced cancer patients molecularly characterized by high MET activity, generally associated with genomic amplification., Results: Using publicly available bioinformatic tools, we discovered that the MET locus transcribes several circRNA molecules, but only one candidate, circMET, was particularly abundant. Deeper molecular analysis revealed that circMET levels positively correlated with MET expression and activity, especially in MET-amplified cells. We developed a circMET-detection strategy and, in parallel, we performed standard FISH and IHC analyses in the same specimens to assess whether circMET quantification could identify patients displaying high MET activity. Longitudinal monitoring of circMET levels in the plasma of selected patients revealed the early emergence of MET amplification as a mechanism of acquired resistance to molecular therapies., Conclusions: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
42. Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications.
- Author
-
Toyokawa G, Bersani F, Bironzo P, Picca F, Tabbò F, Haratake N, Takenaka T, Seto T, Yoshizumi T, Novello S, Scagliotti GV, and Taulli R
- Subjects
- Humans, Drug Resistance, Neoplasm genetics, Protein Kinase Inhibitors therapeutic use, Oncogenes, Mutation, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Antineoplastic Agents therapeutic use
- Abstract
The identification of actionable targets in oncogene-addicted non-small cell lung cancer (NSCLC) has fueled biomarker-directed strategies, especially in advanced stage disease. Despite the undeniable success of molecular targeted therapies, duration of clinical response is relatively short-lived. While extraordinary efforts have defined the complexity of tumor architecture and clonal evolution at the genetic level, not equal interest has been given to the dynamic mechanisms of phenotypic adaptation engaged by cancer during treatment. At the clinical level, molecular targeted therapy of EGFR-mutant and ALK-rearranged tumors often results in epithelial-to-mesenchymal transition (EMT) and histological transformation of the original adenocarcinoma without the acquisition of additional genetic lesions, thus limiting subsequent therapeutic options and patient outcome. Here we provide an overview of the current understanding of the genetic and non-genetic molecular circuits governing this phenomenon, presenting current strategies and potentially innovative therapeutic approaches to interfere with lung cancer cell plasticity., Competing Interests: Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
43. Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
- Author
-
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S, Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C, Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D'Ambrosio L, Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S, Bironzo P, and Sangiolo D
- Subjects
- Humans, Mice, Animals, Cisplatin pharmacology, Cisplatin therapeutic use, Neoplasm Recurrence, Local, Lymphocytes metabolism, Cell Line, Tumor, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung pathology
- Abstract
Purpose: Antibodies against the lymphocyte PD-1 (aPD-1) receptor are cornerstone agents for advanced non-small cell lung cancer (NSCLC), based on their ability to restore the exhausted antitumor immune response. Our study reports a novel, lymphocyte-independent, therapeutic activity of aPD-1 against NSCLC, blocking the tumor-intrinsic PD-1 receptors on chemoresistant cells., Experimental Design: PD-1 in NSCLC cells was explored in vitro at baseline, including stem-like pneumospheres, and following treatment with cisplatin both at transcriptional and protein levels. PD-1 signaling and RNA sequencing were assessed. The lymphocyte-independent antitumor activity of aPD-1 was explored in vitro, by PD-1 blockade and stimulation with soluble ligand (PD-L1s), and in vivo within NSCLC xenograft models., Results: We showed the existence of PD-1+ NSCLC cell subsets in cell lines and large in silico datasets (Cancer Cell Line Encyclopedia and The Cancer Genome Atlas). Cisplatin significantly increased PD-1 expression on chemo-surviving NSCLC cells (2.5-fold P = 0.0014), while the sequential treatment with anti-PD-1 Ab impaired their recovery after chemotherapy. PD-1 was found to be associated with tumor stemness features. PD-1 expression was enhanced in NSCLC stem-like pneumospheres (P < 0.0001), significantly promoted by stimulation with soluble PD-L1 (+27% ± 4, P < 0.0001) and inhibited by PD-1 blockade (-30% ± 3, P < 0.0001). The intravenous monotherapy with anti-PD-1 significantly inhibited tumor growth of NSCLC xenografts in immunodeficient mice, without the contribution of the immune system, and delayed the occurrence of chemoresistance when combined with cisplatin., Conclusions: We report first evidence of a novel lymphocyte-independent activity of anti-PD-1 antibodies in NSCLC, capable of inhibiting chemo-surviving NSCLC cells and exploitable to contrast disease relapses following chemotherapy. See related commentary by Augustin et al., p. 505., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
44. Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer.
- Author
-
Mariniello A, Tabbò F, Indellicati D, Tesauro M, Rezmives NA, Reale ML, Listì A, Capelletto E, Carnio S, Bertaglia V, Mecca C, Consito L, De Filippis M, Bungaro M, Paratore C, Di Maio M, Passiglia F, Righi L, Sangiolo D, Novello S, Geuna M, and Bironzo P
- Subjects
- Humans, B7-H1 Antigen metabolism, Bronchoalveolar Lavage Fluid, Interferon-gamma metabolism, Programmed Cell Death 1 Receptor metabolism, Lung Neoplasms immunology, T-Lymphocyte Subsets immunology
- Abstract
Background: Lung cancer (LC) tissue for immunological characterization is often scarce. We explored and compared T cell characteristics between broncho-alveolar lavage from tumor affected (t-BAL) and contralateral lung (cl-BAL), with matched peripheral blood (PB)., Methods: BAL and PB were collected during bronchoscopy for diagnostic and/or therapeutic purposes in patients with monolateral primary lesion., Results: Of 33 patients undergoing BAL and PB sampling, 21 had histologically-confirmed LC. Most cases were locally-advanced or metastatic non-small cell LC. T cell characteristics were not significantly different in t-BAL vs. cl-BAL. Compared to PB, CD8 T cells in BAL presented features of immune activation and exhaustion (high PD-1, low IFN-g production). Accordingly, regulatory CD4 T cells were also higher in BAL vs. PB. When dichotomizing T cell density in t-BAL in high and low, we found that PD-L1 expression in LC was associated with T cell density in t-BAL. T-BAL with high T cell density had higher %IFN-g+CD8 T cells and lower %T-regs., Conclusion: In BAL from advanced LC patients, T cells present features of exhaustion. T cells in t-BAL could be the best surrogate of tumor-infiltrating T cell, and future studies should evaluate T cell phenotype and density as potential biomarkers for cancer immunotherapy outcome.
- Published
- 2022
- Full Text
- View/download PDF
45. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
- Author
-
Tabbò F, Muscarella LA, Gobbini E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, and Righi L
- Subjects
- Anaplastic Lymphoma Kinase genetics, Crizotinib therapeutic use, Humans, Oncogene Proteins, Fusion genetics, Oncogene Proteins, Fusion therapeutic use, Protein Kinase Inhibitors therapeutic use, RNA, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Introduction: Anaplastic lymphoma kinase (ALK) fusions identify a limited subset of non-small cell lung cancer (NSCLC) patients, whose therapeutic approach have been radically changed in recent years. However, diagnostic procedures and clinical-radiological responses to specific targeted therapies remain heterogeneous and intrinsically resistant or poor responder patients exist., Methods: A total of 290 patients with advanced NSCLC defined as ALK+ by immunohistochemistry (IHC) and/or fluorescent in situ hybridisation (FISH) test and treated with single or sequential multiple ALK inhibitors (ALKi) from 2011 to 2017 have been retrospectively retrieved from a multicentre Italian cancer network database. In 55 patients with enough leftover tumour tissue, specimens were analysed with both targeted and customised next generation sequencing panels. Identified fusion variants have been correlated with clinical outcomes., Results: Of the 55 patients, 24 received crizotinib as first-line therapy, 1 received ceritinib, while 30 received chemotherapy. Most of the patients (64%) received ALKi in sequence. An ALK fusion variant was identified in 73% of the cases, being V3 variant (E6A20) the most frequent, followed by V1 (E13A20) and more rare ones (e.g. E6A19). In three specimens, four new EML4-ALK fusion breakpoints have been reported. Neither fusion variants nor brain metastases were significantly associated with overall survival (OS), while it was predictably longer in patients receiving a sequence of ALKi. The presence of V1 variant was associated with progression-free survival (PFS) improvement when crizotinib was used (p = 0.0073), while it did not affect cumulative PFS to multiple ALKi., Conclusion: Outcomes to sequential ALKi administration were not influenced by fusion variants. Nevertheless, in V1+ patients a prolonged clinical benefit was observed. Fusion variant identification by NGS technology may add relevant information about rare chromosomal events that could be potentially correlated to worse outcomes., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
46. Expert consensus on perioperative treatment for non-small cell lung cancer.
- Author
-
Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbini E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Tam TCC, Tsuchida M, Uchino J, Voltolini L, Wang J, and Gao S
- Abstract
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-527/coif). CZ serves as an Editor-in-Chief of Translational Lung Cancer Research from August 2014 to July 2022. SHL serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. GM serves as an unpaid editorial board member of Translational Lung Cancer Research from February 2016 to July 2023. CG serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023, and received honoraria as speaker bureau or advisory board member or consulting fees form Menarini, Roche, Eli Lilly, Boehringer, Amgen, Pfizer, Novartis, MSD, BMS, Astra Zeneca, Takeda, Novartis, GSK, Karyopharm. Qing Z received lecture and presentations fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi. AB received consulting fees as an Advisory Board with Astra Zeneca, BD, Ethicon, Medtronic, Roche, and is the president of European Society of Thoracic Surgeons. TJ received consulting fees from Roche, Merck, MSD, Puma, AstraZeneca, BMS, Amgen, Gilead, Specialised Therapeutics. DHO reports research funding (to institution) from Genentech, BMS, Merck, Pfizer, Palobiofarma, and Onc. AI. MR received honoraria for lectures and expert meetings from Astrazeneca, and also received honoraria for lectures and expert meetings as well as travel expenses from Abex. KS received a research grant from Boehringer-Ingelheim, through Kindai University Faculty of Medicine, has received consulting fees from AstraZeneca, and has received honoraria from Chugai, Taiho, and AstraZeneca. FT received speaker bureau from AstraZeneca. The other authors have no conflicts of interest to declare.
- Published
- 2022
- Full Text
- View/download PDF
47. Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
- Author
-
Tabbò F, DE Filippis M, Jacobs F, and Novello S
- Subjects
- Humans, Organophosphorus Compounds, Protein-Tyrosine Kinases therapeutic use, Proto-Oncogene Proteins therapeutic use, Pyrimidines, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms pathology
- Abstract
The treatment landscape of advanced non-small cell lung cancer (NSCLC) patients has dramatically changed over the past 10 years, particularly thanks to the advent and development of several tyrosine kinase inhibitors (TKI) targeting oncogenic drivers. Among them, patients bearing anaplastic lymphoma kinase (ALK) translocations, which are causative of 3-5% of all advanced NSCLC, have seen dramatically improved their clinical outcomes moving life expectancy at 5 years from less than 5% to 50%. In fact, multiple ALK inhibitors (ALKi) entered in the therapeutic algorithm of ALK+ patients, multiplying their treatment opportunities. Remarkably, in the near future we could take advantage of up to different 6 molecules for the first-line approach (crizotinib, ceritinib, alectinib, brigatinib, plus ensartinib and lorlatinib). Among available ALKi, brigatinib, a second-generation (2G) inhibitor, showed notable activity in this setting, also against central nervous system (CNS) disease, and a good safety profile, supporting its approval as upfront treatment based on the ALTA-1L trial results. With a peculiar profile of enzymatic targets, brigatinib represents a valuable opportunity in the ALK targeting journey, albeit having to balance its safety profile. The abundance of therapeutic options for these patients poses nontrivial questions; in absence of direct comparisons of efficacy is not easy to define the best approach and, more compelling, the correct administration sequence in order to give the best therapeutic chances to ALK+ lung cancer patients. In such wide variety of options, we reviewed the preclinical and clinical efficacy data of brigatinib, its pharmacological and safety profile, like also actual and potential future applications in the ALK+ NSCLC scenario. Through a spurious exercise of an indirect comparison with other available 2G ALKi, we tent to summarize the required knowledge to properly choose the best drug at the right time. Furthermore, we reviewed available data on molecular resistance mechanisms and putative therapeutic applications in other contexts, such as ROS1+ NSCLC patients or EGFR+ ones progressing to osimertinib.
- Published
- 2022
- Full Text
- View/download PDF
48. The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences.
- Author
-
Fogli S, Tabbò F, Capuano A, Del Re M, Passiglia F, Cucchiara F, Scavone C, Gori V, Novello S, Schmidinger M, and Danesi R
- Subjects
- Drug Interactions, Humans, Neoplasms drug therapy, Neoplasms enzymology, Neoplasms genetics, Neoplasms pathology, Protein Kinase Inhibitors pharmacokinetics, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins c-met antagonists & inhibitors, Proto-Oncogene Proteins c-met genetics, Proto-Oncogene Proteins c-met metabolism, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Receptor Protein-Tyrosine Kinases metabolism
- Abstract
c-Met inhibitors are a class of drugs that include nonselective and selective molecules. These drugs can differ in terms of pharmacodynamic and pharmacokinetic properties that may be clinically relevant. c-Met inhibitors with high potency and selectivity may allow achieving optimal c-Met inhibition in c-Met-driven tumors while reducing unwanted off-target toxicities due to activation of multiple kinases. Nonselective drugs can instead be considered in tumors that also recognize other drivers (e.g., ALK, ROS, VEGF). Improved understanding of the clinical pharmacokinetics of c-Met inhibitors can help avoid drug-drug interactions and optimize schedules for continuous in vivo inhibition of c-Met phosphorylation. The current review article provides a detailed overview of the clinical pharmacology of molecules used in c-Met-driven tumors., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
49. HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway.
- Author
-
Guo K, Ma Z, Zhang Y, Han L, Shao C, Feng Y, Gao F, Di S, Zhang Z, Zhang J, Tabbò F, Ekman S, Suda K, Cappuzzo F, Han J, Li X, and Yan X
- Subjects
- Animals, Carcinoma, Non-Small-Cell Lung pathology, Cell Proliferation, Female, Humans, Lung Neoplasms pathology, Male, Mice, Mice, Nude, Neoplasm Metastasis, Retrospective Studies, Carcinoma, Non-Small-Cell Lung genetics, Deubiquitinating Enzymes metabolism, Fibroblast Growth Factors metabolism, Histone Deacetylases metabolism, Lung Neoplasms genetics, beta Catenin metabolism
- Abstract
Background: Histone deacetylases (HDACs) play crucial roles in cancers, but the role and mechanism of HDAC7 in NSCLC have not been fully understood., Methods: A total of 319 patients with non-small cell lung cancer (NSCLC) who underwent surgery were enrolled in this study. Immunohistochemistry and Kaplan-Meier survival analysis were performed to investigate the relationship between HDAC7, fibroblast growth factor 18 (FGF18) expression, and clinicopathologic characteristics. Cell functional experiments were implemented both in vivo and in vitro to investigate the effects on NSCLC cell proliferation and metastasis. Recombinant lentivirus-meditated in vivo gene overexpression or knockdown, real-time polymerase chain reaction (PCR), western blotting, and coimmunoprecipitation assays were applied to clarify the underlying molecular mechanism of HDAC7 in promoting NSCLC progression., Results: The elevated expression of HDAC7 or FGF18 was positively correlated with poor prognosis, tumor-node-metastasis (TNM) stage, and tumor differentiation of NSCLC patients. NSCLC patients with co-expressed HDAC7 and FGF18 suffered the worst prognosis. HDAC7 overexpression promoted NSCLC proliferation and metastasis by upregulating FGF18. Conversely, overexpression of FGF18 reversed the attenuated ability in tumor growth and metastasis mediated by downregulating HDAC7. In terms of mechanism, our results suggested that the interaction of HDAC7 with β-catenin caused decreased β-catenin acetylation level at Lys49 and decreased phosphorylation level at Ser45. As a consequence, the HDAC7-mediated posttranslational modification of β-catenin facilitated nuclear transfer and activated FGF18 expression via binding to TCF4. Furthermore, deubiquitinase USP10 interacted with and stabilized HDAC7. The suppression of USP10 significantly accelerated the degradation of HDAC7 and weakened NSCLC growth and migration., Conclusions: Our findings reveal that HDAC7 promotes NSCLC progression through being stabilized by USP10 and activating the β-catenin-FGF18 pathway. Targeting this novel pathway may be a promising strategy for further developments in NSCLC therapy., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
50. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
- Author
-
Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, and Ortiz-Cuaran S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung genetics, Clinical Trials as Topic, Humans, Immunotherapy methods, Lung Neoplasms genetics, Mutation, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Vemurafenib therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Molecular Targeted Therapy methods, Proto-Oncogene Proteins B-raf genetics
- Abstract
The advent of high-throughput sequencing has allowed to profoundly interrogate the molecular landscape of non-small cell lung cancer (NSCLC) in the last years. These findings constitute the opportunity to better stratify these patients in order to address specific treatments to well-defined oncogene-restricted subgroups. Among them, BRAF-mutated lung cancers represent around 4% of NSCLC, thus identifying a clinically relevant population that should be aptly managed. Pivotal phase II trials have demonstrated the efficacy of combinatorial treatment - dabrafenib plus trametinib, targeting both BRAF and MEK - for patients harboring V600E mutations, making this specific BRAF alteration a mandatory requirement in the genetic portrait of advanced non-squamous lung cancer patients. However, around half of BRAF+ NSCLC patients remain orphan of targeted approaches. Here we review the available evidence, mainly from a clinical perspective, of therapeutic strategies for both V600E and non-V600 patients, in terms of small molecule, immune checkpoint inhibitors and forthcoming integrated strategies. Looking at on-going clinical trials, a special attention is dedicated to emergent molecules and combinatorial strategies that not only will improve outcomes of classical V600E, but also will make concrete the chance of tailored treatments for the majority of BRAF-mutated patients., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.